Shopping Cart
Remove All
Your shopping cart is currently empty
Thalidomide-O-amido-PEG2-C2-NH2, which combines an E3 ligase ligand with a linker, serves as an immunomodulator for cancer treatment.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 100 mg | Inquiry | Backorder | Backorder | |
| 500 mg | Inquiry | Backorder | Backorder |
| Description | Thalidomide-O-amido-PEG2-C2-NH2, which combines an E3 ligase ligand with a linker, serves as an immunomodulator for cancer treatment. |
| In vitro | PROTACs consist of two distinct ligands joined by a linker: one ligand targets an E3 ubiquitin ligase, while the other targets the desired protein. These compounds leverage the intracellular ubiquitin-proteasome system to specifically degrade target proteins. |
| Synonyms | Thalidomide-O-amido-PEG2-C2-NH2, E3LigaseLigand-LinkerConjugates24, Cereblon Ligand-Linker Conjugates 10 |
| Molecular Weight | 462.459 |
| Formula | C21H26N4O8 |
| Cas No. | 1957235-74-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.